Growth Story Still Intact For Tonix Pharmaceuticals Holding Corp. (TNXP)

After grabbing 4.5 million shares, the institutional investor is now in possession of 4.5 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.39% having worth around $3.15 million. Moreover, The Vanguard Group, Inc. increased its share by 0.12 million to have a control over 0.97 million shares. And Acadian Asset Management LLC raised its holdings to 0.9 million shares by acquiring 0.9 million shares or 1.48% of the stake.

Tonix Pharmaceuticals Holding Corp. (TNXP) concluded trading on 03/16/23 at a closing price of $0.60, with 0.83 million shares of worth about $0.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -33.53% during that period and on Thursday the price saw a gain of about 6.64%. Currently the company’s common shares owned by public are about 60.87M shares, out of which, 60.84M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the TNXP stock and their offered price forecasts bring an average price target of $6.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $6.50 and could fall to a lowest price of $6.00. The stock’s current price level is 90.52% above of average price target set by the analysts, while a rise to estimated low would result in gain of 90.0% for the stock. However, touching the estimated high of $6.50 would mean a gain of 90.77% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Tonix Pharmaceuticals Holding Corp. Vanguard Total Stock Market Index is currently holding 1.86 million shares of worth totaling $1.3 million. The company recently came buying 1.28 million shares which brought its stake up to 3.05% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 47338.0 shares, after which its hold over company’s outstanding shares expand to 0.72%, leaving 0.44 million shares with the mutual fund that have a worth of about $0.31 million. Fidelity Extended Market Index Fu, after buying 0.32 million shares, have now control over 0.52% of the stake in the company. It holds 0.1 million shares of worth $0.22 million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) started trading at $0.575, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.6040, or with a gain of 6.64%. Stock saw a price change of -7.37% in past 5 days and over the past one month there was a price change of -41.81%. Year-to-date (YTD), TNXP shares are showing a performance of 53.77% which decreased to -91.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $8.48 during that period. The average intraday trading volume for Tonix Pharmaceuticals Holding Corp. shares is 4.03 million. The stock is currently trading -18.42% below its 20-day simple moving average (SMA20), while that difference is down -35.04% for SMA50 and it goes to -39.74% lower than SMA200.

Tang Capital Management LLC acquired 4.5 million shares of Tonix Pharmaceuticals Holding Corp. having value of about $3.15 million. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) currently have 60.87M outstanding shares and institutions hold larger chunk of about 10.50% of that. Holding of mutual funds in the company is about 10.50% while other institutional holders and individual stake holders have control over 5.23% and 0.05% of the stake respectively.

The stock has a current market capitalization of $37.91M and its 3Y-monthly beta is at 2.19. It has posted earnings per share of -$5.62 in the same period. It has Quick Ratio of 11.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNXP, volatility over the week remained 11.27% while standing at 11.37% over the month.

Analysts are in expectations that Tonix Pharmaceuticals Holding Corp. (TNXP) stock would likely to be making an EPS of -$0.86 in the current quarter, while forecast for next quarter EPS is -$0.93 and it is -$3.14 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.41 which is -$0.54 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$2.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 53.60% while it is estimated to increase by 18.90% in next year.

Analysts at 2 brokerage firms have issued recommendations for the Tonix Pharmaceuticals Holding Corp. (TNXP)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Coverage by ROTH Capital stated Tonix Pharmaceuticals Holding Corp. (TNXP) stock as a Buy in their note to investors on April 18, 2019, suggesting a price target of $4 for the stock. Stock get an Outperform rating from Oppenheimer on February 17, 2016.